Buchumschlag

Thalidomide in multiple myeloma

Thalidomide (Thal) has antiangiogenic and immunomodulatory activity. Clinical research provided clear evidence that Thal is one of the most active drugs for the treatment of multiple myeloma leading to decrease of monoclonal protein of at least 50% in 30% of patients with relapsed or refractory mult...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Möhler, Thomas (VerfasserIn) , Hillengaß, Jens (VerfasserIn) , Glasmacher, A. (VerfasserIn) , Goldschmidt, Hartmut (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: [2006]
In: Current pharmaceutical biotechnology
Year: 2006, Jahrgang: 7, Heft: 6, Pages: 431-440
ISSN:1873-4316
DOI:10.2174/138920106779116919
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2174/138920106779116919
Verlag, lizenzpflichtig, Volltext: https://www.eurekaselect.com/article/3325
Volltext
Verfasserangaben:T.M. Moehler, J. Hillengass, A. Glasmacher and H. Goldschmidt

MARC

LEADER 00000caa a22000002c 4500
001 1787392481
003 DE-627
005 20230428005753.0
007 cr uuu---uuuuu
008 220128s2006 xx |||||o 00| ||eng c
024 7 |a 10.2174/138920106779116919  |2 doi 
035 |a (DE-627)1787392481 
035 |a (DE-599)KXP1787392481 
035 |a (OCoLC)1341439559 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Möhler, Thomas  |e VerfasserIn  |0 (DE-588)1014877261  |0 (DE-627)705298051  |0 (DE-576)34979572X  |4 aut 
245 1 0 |a Thalidomide in multiple myeloma  |c T.M. Moehler, J. Hillengass, A. Glasmacher and H. Goldschmidt 
264 1 |c [2006] 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 28.01.2022 
520 |a Thalidomide (Thal) has antiangiogenic and immunomodulatory activity. Clinical research provided clear evidence that Thal is one of the most active drugs for the treatment of multiple myeloma leading to decrease of monoclonal protein of at least 50% in 30% of patients with relapsed or refractory multiple myeloma. Randomized trials based on a large body of evidence from phase II trials determined that Thal significantly increases total response rate in combination regimens (dexamethasone [Dex] and or chemotherapy) for relapsed as well as newly diagnosed patients. Thal also decreases time to response in combination therapy approaches. Thal has therefore been recognized by leading organizations as part of the treatment concept for patients with relapsed or refractory disease. Strict guidelines apply for the treatment and monitoring of Thal therapy to prevent the teratogenic effects of Thal and to monitor and prevent other potential adverse events as neuropathy and thrombosis. Additional randomized studies will now define the status of Thal for newly diagnosed patients and will be the basis for the approval in Europe and other countries world wide. 
700 1 |a Hillengaß, Jens  |d 1974-  |e VerfasserIn  |0 (DE-588)124918549  |0 (DE-627)368073823  |0 (DE-576)294568298  |4 aut 
700 1 |a Glasmacher, A.  |e VerfasserIn  |4 aut 
700 1 |a Goldschmidt, Hartmut  |d 1956-  |e VerfasserIn  |0 (DE-588)102258023X  |0 (DE-627)717003809  |0 (DE-576)365637386  |4 aut 
773 0 8 |i Enthalten in  |t Current pharmaceutical biotechnology  |d Hilversum : Bentham Science Publ., 2000  |g 7(2006), 6, Seite 431-440  |h Online-Ressource  |w (DE-627)327962445  |w (DE-600)2044611-1  |w (DE-576)273880926  |x 1873-4316  |7 nnas  |a Thalidomide in multiple myeloma 
773 1 8 |g volume:7  |g year:2006  |g number:6  |g pages:431-440  |g extent:10  |a Thalidomide in multiple myeloma 
856 4 0 |u https://doi.org/10.2174/138920106779116919  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.eurekaselect.com/article/3325  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220128 
993 |a Article 
994 |a 2006 
998 |g 102258023X  |a Goldschmidt, Hartmut  |m 102258023X:Goldschmidt, Hartmut  |d 910000  |d 910100  |d 50000  |e 910000PG102258023X  |e 910100PG102258023X  |e 50000PG102258023X  |k 0/910000/  |k 1/910000/910100/  |k 0/50000/  |p 4  |y j 
998 |g 124918549  |a Hillengaß, Jens  |m 124918549:Hillengaß, Jens  |d 910000  |d 910100  |e 910000PH124918549  |e 910100PH124918549  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 1014877261  |a Möhler, Thomas  |m 1014877261:Möhler, Thomas  |d 910000  |d 910100  |e 910000PM1014877261  |e 910100PM1014877261  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1787392481  |e 4047041521 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"person":[{"display":"Möhler, Thomas","family":"Möhler","given":"Thomas","role":"aut"},{"given":"Jens","role":"aut","display":"Hillengaß, Jens","family":"Hillengaß"},{"display":"Glasmacher, A.","family":"Glasmacher","role":"aut","given":"A."},{"display":"Goldschmidt, Hartmut","family":"Goldschmidt","given":"Hartmut","role":"aut"}],"id":{"doi":["10.2174/138920106779116919"],"eki":["1787392481"]},"name":{"displayForm":["T.M. Moehler, J. Hillengass, A. Glasmacher and H. Goldschmidt"]},"physDesc":[{"extent":"10 S."}],"recId":"1787392481","relHost":[{"language":["eng"],"part":{"volume":"7","extent":"10","pages":"431-440","year":"2006","issue":"6","text":"7(2006), 6, Seite 431-440"},"title":[{"title":"Current pharmaceutical biotechnology","subtitle":"the international journal for timely in-depth reviews in pharmaceutical biotechnology","title_sort":"Current pharmaceutical biotechnology"}],"note":["Gesehen am 15.04.2024"],"pubHistory":["1.2000 -"],"origin":[{"publisherPlace":"Hilversum","dateIssuedKey":"2000","publisher":"Bentham Science Publ.","dateIssuedDisp":"2000-"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Thalidomide in multiple myelomaCurrent pharmaceutical biotechnology","recId":"327962445","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["327962445"],"issn":["1873-4316"],"zdb":["2044611-1"]}}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2006","dateIssuedDisp":"[2006]"}],"note":["Gesehen am 28.01.2022"],"title":[{"title_sort":"Thalidomide in multiple myeloma","title":"Thalidomide in multiple myeloma"}]} 
SRT |a MOEHLERTHOTHALIDOMID2006 

Ähnliche Einträge